FDA Hands Out Fast-Track Voucher for Disease-Fighting Drug
Published Date: 4/23/2025
Notice
Summary
The FDA just gave Ridgeback Biotherapeutics a special priority review voucher for their EBANGA medicine, which helps protect against serious health threats. This voucher speeds up future drug reviews, making it easier and faster to get important medicines approved. It’s a big win for public health and shows the FDA’s commitment to fighting dangerous diseases quickly.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Priority Review Voucher Awarded to Ridgeback
The FDA awarded a priority review voucher to the sponsor Ridgeback Biotherapeutics for EBANGA (ansuvimab-zykl) for injection, which the FDA says met the material threat medical countermeasure criteria. EBANGA was approved on December 21, 2020, and the voucher can be used by the sponsor to obtain priority review for a future drug application.
Faster Reviews Could Speed Access to Medicines
The FDA says the priority review voucher is for a material threat medical countermeasure and can be used to obtain priority review for future drug applications, which speeds up future drug reviews and can make it easier and faster to get important medicines approved.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11762 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Procedures for the Safe Processing and Importing of Fish and Fishery Products
The FDA is asking for approval to keep collecting info from seafood processors and importers to make sure fish products are safe using a system called HACCP. This affects anyone who processes or imports fish and requires them to keep records showing they’re following safety rules. Comments on this plan are open until July 13, 2026, and there’s no new cost, just a continuation of current paperwork.
2026-11740 — Medical Devices; Immunology and Microbiology Devices; Classification of the Spinal Muscular Atrophy Newborn Screening Test System
The FDA is officially putting the Spinal Muscular Atrophy (SMA) newborn screening test into class II, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make the test safer and easier to get to babies who need it, starting June 11, 2026, with the classification effective since November 2022. Labs and device makers will benefit from clearer rules and faster access, helping catch SMA early without extra costs or delays.
2026-11739 — Medical Devices; Immunology and Microbiology Devices; Classification of the Simple Point-of-Care Device to Directly Detect SARS-CoV-2 Viral Targets From Clinical Specimens in Near-Patient Settings
The FDA is officially putting simple COVID-19 rapid test devices into a safer, easier-to-manage category called Class II. This change means these tests can get to patients faster and with fewer hoops to jump through, while still making sure they work well and stay safe. Starting June 11, 2026, companies making these tests will follow new rules that help speed up innovation without extra costs.
2026-11760 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Establishment, Maintenance, and Availability of Records; Additional Traceability Records for Certain Foods
The FDA is asking for approval to collect extra records from food businesses that handle certain high-risk foods. This helps track food sources quickly to keep everyone safe. Food companies should get ready to keep and share these new records, and comments on this plan are due by July 13, 2026.
2026-11578 — Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, and Related Information
The FDA just gave a thumbs-up to adding bemotrizinol as a new active ingredient in sunscreens, letting it be used up to 6% concentration. This means sunscreen makers can now include this ingredient, which is safe and effective, in their products. The change is official as of June 10, 2026, and could lead to better sun protection options without extra costs for consumers.
2026-11589 — Medical Devices; Ear, Nose, and Throat Devices; Classification of the Combined Acoustic and Electrical External Stimulation Device for the Relief of Tinnitus
The FDA has officially placed the combined acoustic and electrical external stimulation device for tinnitus relief into class II, meaning it now has special safety rules but fewer regulatory hurdles. This change helps patients get access to this innovative device faster and ensures it’s safe and effective. The new classification is effective June 10, 2026, with the rules applying retroactively from March 6, 2023.
Previous / Next Documents
Previous: 2025-06969 — Notice of Approval of Product Under Voucher: Material Threat Medical Countermeasure Priority Review Voucher; EYLEA HD (aflibercept)
The FDA just gave a big thumbs-up to EYLEA HD, a medicine that got a fast-track review thanks to a special priority voucher. This means the company behind EYLEA HD moved quickly through the approval process because their product helps protect against serious health threats. Patients and healthcare providers can expect this medicine to be available sooner, with no extra cost signals mentioned.
Next: 2025-06971 — Proposed Agency Information Collection Activities; Comment Request
The NCUA wants to keep collecting info with the Call Report (Form 5300) for three more years and has updated the instructions to make them clearer. Credit unions will need to follow these new rules starting with the September 30, 2025 report. This proposal is open for public comments before it gets final approval, so now’s the time to speak up!